文献速递甲状腺与浅表头颈US

一种实用的甲状腺结节超声造影报告系统

A Practical CEUS Thyroid Reporting System for Thyroid Nodules.
PubMed 文献 · Radiology · 2022-06-14

该回顾性研究基于756例患者801个甲状腺结节的非增强超声与超声造影特征构建甲状腺影像报告和数据系统(CEUS TI-RADS),并与其它系统比较恶性风险分层效能;CEUS TI-RADS 的 AUC 为0.93(95%CI:0.92,0.95),活检恶性检出率66%(157/239),不必要活检率34%(82/239),外部验证 AUC 分别为0.89(95%CI:0.84,0.92)和0.90(95%CI:0.85,0.94)。

要点

  • CEUS TI-RADS 的 AUC 为0.93(95%CI:0.92,0.95),高于所有其他对比系统(P < .001)。
  • CEUS TI-RADS 活检恶性检出率为66%(157/239),不必要活检率为34%(82/239)。
  • 外部验证集1和集2的 AUC 分别为0.89(95%CI:0.84,0.92)和0.90(95%CI:0.85,0.94)。

核心结论

  • 基于非增强超声与超声造影定性特征构建的 CEUS TI-RADS 可实现甲状腺结节恶性风险分层,其 AUC 为0.93(95%CI:0.92,0.95),与所有其他系统比较 P < .001。

研究设计与样本

  • 回顾性研究,纳入2018年1月至2019年12月接受非增强超声、超声造影和细针穿刺并获最终诊断的756例患者共801个甲状腺结节,采用单因素和多因素 logistic 回归分析超声特征构建 CEUS TI-RADS,并进行内部交叉验证和外部验证。

关键影像表现/征象

  • 独立预测超声特征包括超声造影下的结节成分、回声、结节形状、结节边缘、强回声灶、甲状腺外侵犯、增强方向、峰值强度和环状增强。

诊断标准与关键数值

  • CEUS TI-RADS 的 AUC 为0.93(95%CI:0.92,0.95),与所有其他系统比较 P < .001。
  • CEUS TI-RADS 活检恶性检出率为66%(157/239),不必要活检率为34%(82/239)。
  • 外部验证集1的 AUC 为0.89(95%CI:0.84,0.92),活检恶性检出率为61%(65/106),不必要活检率为39%(41/106)。
  • 外部验证集2的 AUC 为0.90(95%CI:0.85,0.94),活检恶性检出率为57%(56/99),不必要活检率为43%(43/99)。

临床应用与阅片要点

  • CEUS TI-RADS 依据非增强超声和超声造影定性特征对甲状腺结节进行恶性风险分层,可用于减少不必要的活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The role of contrast-enhanced US (CEUS) in reducing unnecessary biopsies of thyroid nodules has received little attention. Purpose To construct and externally validate a thyroid imaging reporting and data system (TI-RADS) based on nonenhanced US and CEUS to stratify the malignancy risk of thyroid nodules. Materials and Methods This retrospective study evaluated 756 patients with 801 thyroid nodules who underwent nonenhanced US, CEUS, and fine-needle aspiration and received a final diagnosis from January 2018 to December 2019. Qualitative US features of the thyroid nodules were analyzed with univariable and multivariable logistic regression to construct a CEUS TI-RADS. The CEUS TI-RADS was validated with use of internal cross-validation and external validation. Results A total of 801 thyroid nodules in 590 female (mean age, 44 years ± 13) and 166 male (mean age, 47 years ± 13 [SD]) patients were included. Independent predictive US features included nodule composition at CEUS, echogenicity, nodule shape, nodule margin, echogenic foci, extrathyroidal extension, enhancement direction, peak intensity, and ring enhancement. The CEUS TI-RADS showed a higher area under the receiver operating characteristic curve of 0.93 (95% CI: 0.92, 0.95; P < .001 in comparison with all other systems), a biopsy yield of malignancy of 66% (157 of 239 nodules), and an unnecessary biopsy rate of 34% (82 of 239 nodules). In the external validation, the area under the receiver operating characteristic curve, biopsy yield of malignancy, and unnecessary biopsy rate of CEUS TI-RADS were 0.89 (95% CI: 0.84, 0.92), 61% (65 of 106 nodules), and 39% (41 of 106 nodules) for the first external validation set and 0.90 (95% CI: 0.85, 0.94), 57% (56 of 99 nodules), and 43% (43 of 99 nodules) for the second external validation set. Conclusion A contrast-enhanced US (CEUS) thyroid imaging reporting and data system was created with thyroid nodule malignancy risk stratification according to the simplified regression coefficients of nonenhanced US and qualitative features of CEUS. Clinical trials registration no. ChiCTR2000028712 Published under a CC BY 4.0 license. Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ruan, Xu, Cai, et al. A Practical CEUS Thyroid Reporting System for Thyroid Nodules. Radiology. 2022. PMID: 35699576. doi:10.1148/radiol.212319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。